MetaCap

Bioventus (BVS) vs Avita Medical (RCEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avita Medical (RCEL) has outperformed Bioventus (BVS) over the past year, gaining 312.1% versus a gain of 36.5%. Over five years, RCEL leads with a +10.8% price change compared with -21.0% for BVS. Bioventus is the larger company by market cap ($676.5 million vs $495.0 million), about 1.4 times the size, while Avita Medical is growing revenue faster (+11.5% vs -0.9%).

Bioventus converts more of its revenue into profit, with a net margin of 4.0% versus -67.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BVS+36.46%RCEL+312.14%
+385%+176%-33%
Nov 21, 20251 yearNov 20, 2026
BVS-29.53%RCEL+4.20%
+45%-27%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BVS versus RCEL key metrics
MetricBVSRCEL
Share price$9.88$15.62
Market cap$676.53M$494.96M
1-day change-0.70%-2.31%
YTD return+32.80%+352.75%
1-year return+36.46%+312.14%
5-year return-21.02%+10.78%
P/E ratio (TTM)12.20—
Forward P/E11.13—
EPS (TTM)$0.81$-1.17
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$568.09M$71.61M
Revenue growth (YoY)-0.91%+11.45%
Net income (latest FY)$22.73M$-48.59M
Gross margin68.33%82.13%
Operating margin9.50%-59.40%
Net margin4.00%-67.85%
52-week high$15.89$18.43
52-week low$7.02$3.22
Distance from 52-week high-37.83%-15.25%
Analyst consensusnonestrong_buy
Avg. price target upside+68.02%+32.46%
Average volume536.81K417.02K
Shares outstanding68.47M31.69M
Employees960226
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RCEL has outperformed BVS by 275.7 percentage points over the past year.
  • Bioventus is more profitable, keeping 4.0 cents of every revenue dollar as net income versus -67.8 cents for Avita Medical.
  • Avita Medical grew revenue faster in its latest fiscal year (+11.45% vs -0.91%).

About Bioventus

BVS stock →

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.

Health Care · Medical/Dental Instruments · 960 employees

About Avita Medical

RCEL stock →

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.

Health Care · Medical/Dental Instruments · 226 employees

BVS vs RCEL FAQ

Which is bigger, Bioventus or Avita Medical?

Bioventus (BVS) is larger, with a market capitalization of $676.53M compared with $494.96M for Avita Medical (RCEL).

Which stock has performed better over the past year, BVS or RCEL?

RCEL returned +312.14% over the past 12 months, compared with +36.46% for BVS (price return, excluding dividends). Past performance does not predict future results.

Are Bioventus and Avita Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons